Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy

Rita Citraro, Emilio Russo, Francesca Scicchitano, Clementina M van Rijn, Donato Cosco, Carmen Avagliano, Roberto Russo, Giuseppe D'Agostino, Stefania Petrosino, Francesca Guida, Luisa Gatta, Gilles van Luijtelaar, Sabatino Maione, Vincenzo Di Marzo, Antonio Calignano, Giovambattista De Sarro

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

N-palmitoylethanolamine (PEA), an endogenous fatty acid ethanolamide, plays a key role in the regulation of the inflammatory response and pain through, among others, activation of nuclear peroxisome proliferator-activated receptors (PPAR-α). Endogenous cannabinoids play a protective role in several central nervous system (CNS) disorders, particularly those associated with neuronal hyperexcitability. We investigated the effects of PEA and the role of PPAR-α in absence epilepsy using the WAG/Rij rat model. PEA, anandamide (AEA), a PPAR-α antagonist (GW6471) and a synthetic CB1 receptor antagonist/inverse agonist (SR141716) were administered to WAG/Rij rats in order to evaluate the effects on epileptic spike-wave discharges (SWDs) on EEG recordings. We studied also the effects of PEA co-administration with SR141716 and GW6471 and compared these effects with those of AEA to evaluate PEA mechanism of action and focusing on CB1 receptors and PPAR-α. Both PEA and AEA administration significantly decreased SWDs parameters (absence seizures). In contrast, GW6471 was devoid of effects while SR141716 had pro-absence effects. The co-administration of SR141716 with PEA or AEA completely blocked the anti-absence effects of these compounds. GW6471 antagonized PEA's effects whereas it did not modify AEA's effects. Furthermore, we have also measured PEA, AEA and 2-AG (2-arachidonoylglycerol) brain levels identifying significant differences between epileptic and control rats such as decreased PEA levels in both thalamus and cortex that might contribute to absence epilepsy. Our data demonstrate that PEA has anti-absence properties in the WAG/Rij rat model and that such properties depend on PPAR-α and indirect activation of CB1 receptors. This article is part of the Special Issue entitled 'New Targets and Approaches to the Treatment of Epilepsy'.
Original languageEnglish
Pages (from-to)115-126
Number of pages12
JournalNeuropharmacology
Volume69
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Absence Epilepsy
Peroxisome Proliferator-Activated Receptors
Genetic Models
rimonabant
Anticonvulsants
Cannabinoid Receptor CB1
Artificial Receptors
palmidrol
Cannabinoids
Central Nervous System Diseases
Thalamus
Electroencephalography
Epilepsy
Fatty Acids

Keywords

  • animals
  • anticonvulsants
  • arachidonic acids
  • calcium channel blockers
  • cannabinoid receptor antagonists
  • dose-response relationship, drug
  • electroencephalography
  • endocannabinoids
  • epilepsy, absence
  • ethanolamines
  • glycerides
  • injections, intraventricular
  • lipid metabolism
  • male
  • oxazoles
  • PPAR alpha
  • palmitic acids
  • piperidines
  • polyunsaturated alkamides
  • pyrazoles
  • rats
  • rats, wistar
  • receptor, cannabinoid, CB1
  • tyrosine

Cite this

Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy. / Citraro, Rita; Russo, Emilio; Scicchitano, Francesca; van Rijn, Clementina M; Cosco, Donato; Avagliano, Carmen; Russo, Roberto; D'Agostino, Giuseppe; Petrosino, Stefania; Guida, Francesca; Gatta, Luisa; van Luijtelaar, Gilles; Maione, Sabatino; Di Marzo, Vincenzo; Calignano, Antonio; De Sarro, Giovambattista.

In: Neuropharmacology, Vol. 69, 06.2013, p. 115-126.

Research output: Contribution to journalArticle

Citraro, R, Russo, E, Scicchitano, F, van Rijn, CM, Cosco, D, Avagliano, C, Russo, R, D'Agostino, G, Petrosino, S, Guida, F, Gatta, L, van Luijtelaar, G, Maione, S, Di Marzo, V, Calignano, A & De Sarro, G 2013, 'Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy', Neuropharmacology, vol. 69, pp. 115-126. https://doi.org/10.1016/j.neuropharm.2012.11.017
Citraro, Rita ; Russo, Emilio ; Scicchitano, Francesca ; van Rijn, Clementina M ; Cosco, Donato ; Avagliano, Carmen ; Russo, Roberto ; D'Agostino, Giuseppe ; Petrosino, Stefania ; Guida, Francesca ; Gatta, Luisa ; van Luijtelaar, Gilles ; Maione, Sabatino ; Di Marzo, Vincenzo ; Calignano, Antonio ; De Sarro, Giovambattista. / Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy. In: Neuropharmacology. 2013 ; Vol. 69. pp. 115-126.
@article{726801c0c5b14b899f50b5926554332e,
title = "Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy",
abstract = "N-palmitoylethanolamine (PEA), an endogenous fatty acid ethanolamide, plays a key role in the regulation of the inflammatory response and pain through, among others, activation of nuclear peroxisome proliferator-activated receptors (PPAR-α). Endogenous cannabinoids play a protective role in several central nervous system (CNS) disorders, particularly those associated with neuronal hyperexcitability. We investigated the effects of PEA and the role of PPAR-α in absence epilepsy using the WAG/Rij rat model. PEA, anandamide (AEA), a PPAR-α antagonist (GW6471) and a synthetic CB1 receptor antagonist/inverse agonist (SR141716) were administered to WAG/Rij rats in order to evaluate the effects on epileptic spike-wave discharges (SWDs) on EEG recordings. We studied also the effects of PEA co-administration with SR141716 and GW6471 and compared these effects with those of AEA to evaluate PEA mechanism of action and focusing on CB1 receptors and PPAR-α. Both PEA and AEA administration significantly decreased SWDs parameters (absence seizures). In contrast, GW6471 was devoid of effects while SR141716 had pro-absence effects. The co-administration of SR141716 with PEA or AEA completely blocked the anti-absence effects of these compounds. GW6471 antagonized PEA's effects whereas it did not modify AEA's effects. Furthermore, we have also measured PEA, AEA and 2-AG (2-arachidonoylglycerol) brain levels identifying significant differences between epileptic and control rats such as decreased PEA levels in both thalamus and cortex that might contribute to absence epilepsy. Our data demonstrate that PEA has anti-absence properties in the WAG/Rij rat model and that such properties depend on PPAR-α and indirect activation of CB1 receptors. This article is part of the Special Issue entitled 'New Targets and Approaches to the Treatment of Epilepsy'.",
keywords = "animals, anticonvulsants, arachidonic acids, calcium channel blockers, cannabinoid receptor antagonists, dose-response relationship, drug, electroencephalography, endocannabinoids, epilepsy, absence, ethanolamines, glycerides, injections, intraventricular, lipid metabolism, male, oxazoles, PPAR alpha, palmitic acids, piperidines, polyunsaturated alkamides, pyrazoles, rats, rats, wistar, receptor, cannabinoid, CB1, tyrosine",
author = "Rita Citraro and Emilio Russo and Francesca Scicchitano and {van Rijn}, {Clementina M} and Donato Cosco and Carmen Avagliano and Roberto Russo and Giuseppe D'Agostino and Stefania Petrosino and Francesca Guida and Luisa Gatta and {van Luijtelaar}, Gilles and Sabatino Maione and {Di Marzo}, Vincenzo and Antonio Calignano and {De Sarro}, Giovambattista",
note = "Copyright {\circledC} 2012 Elsevier Ltd. All rights reserved.",
year = "2013",
month = "6",
doi = "10.1016/j.neuropharm.2012.11.017",
language = "English",
volume = "69",
pages = "115--126",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "PERGAMON-ELSEVIER SCIENCE LTD",

}

TY - JOUR

T1 - Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy

AU - Citraro, Rita

AU - Russo, Emilio

AU - Scicchitano, Francesca

AU - van Rijn, Clementina M

AU - Cosco, Donato

AU - Avagliano, Carmen

AU - Russo, Roberto

AU - D'Agostino, Giuseppe

AU - Petrosino, Stefania

AU - Guida, Francesca

AU - Gatta, Luisa

AU - van Luijtelaar, Gilles

AU - Maione, Sabatino

AU - Di Marzo, Vincenzo

AU - Calignano, Antonio

AU - De Sarro, Giovambattista

N1 - Copyright © 2012 Elsevier Ltd. All rights reserved.

PY - 2013/6

Y1 - 2013/6

N2 - N-palmitoylethanolamine (PEA), an endogenous fatty acid ethanolamide, plays a key role in the regulation of the inflammatory response and pain through, among others, activation of nuclear peroxisome proliferator-activated receptors (PPAR-α). Endogenous cannabinoids play a protective role in several central nervous system (CNS) disorders, particularly those associated with neuronal hyperexcitability. We investigated the effects of PEA and the role of PPAR-α in absence epilepsy using the WAG/Rij rat model. PEA, anandamide (AEA), a PPAR-α antagonist (GW6471) and a synthetic CB1 receptor antagonist/inverse agonist (SR141716) were administered to WAG/Rij rats in order to evaluate the effects on epileptic spike-wave discharges (SWDs) on EEG recordings. We studied also the effects of PEA co-administration with SR141716 and GW6471 and compared these effects with those of AEA to evaluate PEA mechanism of action and focusing on CB1 receptors and PPAR-α. Both PEA and AEA administration significantly decreased SWDs parameters (absence seizures). In contrast, GW6471 was devoid of effects while SR141716 had pro-absence effects. The co-administration of SR141716 with PEA or AEA completely blocked the anti-absence effects of these compounds. GW6471 antagonized PEA's effects whereas it did not modify AEA's effects. Furthermore, we have also measured PEA, AEA and 2-AG (2-arachidonoylglycerol) brain levels identifying significant differences between epileptic and control rats such as decreased PEA levels in both thalamus and cortex that might contribute to absence epilepsy. Our data demonstrate that PEA has anti-absence properties in the WAG/Rij rat model and that such properties depend on PPAR-α and indirect activation of CB1 receptors. This article is part of the Special Issue entitled 'New Targets and Approaches to the Treatment of Epilepsy'.

AB - N-palmitoylethanolamine (PEA), an endogenous fatty acid ethanolamide, plays a key role in the regulation of the inflammatory response and pain through, among others, activation of nuclear peroxisome proliferator-activated receptors (PPAR-α). Endogenous cannabinoids play a protective role in several central nervous system (CNS) disorders, particularly those associated with neuronal hyperexcitability. We investigated the effects of PEA and the role of PPAR-α in absence epilepsy using the WAG/Rij rat model. PEA, anandamide (AEA), a PPAR-α antagonist (GW6471) and a synthetic CB1 receptor antagonist/inverse agonist (SR141716) were administered to WAG/Rij rats in order to evaluate the effects on epileptic spike-wave discharges (SWDs) on EEG recordings. We studied also the effects of PEA co-administration with SR141716 and GW6471 and compared these effects with those of AEA to evaluate PEA mechanism of action and focusing on CB1 receptors and PPAR-α. Both PEA and AEA administration significantly decreased SWDs parameters (absence seizures). In contrast, GW6471 was devoid of effects while SR141716 had pro-absence effects. The co-administration of SR141716 with PEA or AEA completely blocked the anti-absence effects of these compounds. GW6471 antagonized PEA's effects whereas it did not modify AEA's effects. Furthermore, we have also measured PEA, AEA and 2-AG (2-arachidonoylglycerol) brain levels identifying significant differences between epileptic and control rats such as decreased PEA levels in both thalamus and cortex that might contribute to absence epilepsy. Our data demonstrate that PEA has anti-absence properties in the WAG/Rij rat model and that such properties depend on PPAR-α and indirect activation of CB1 receptors. This article is part of the Special Issue entitled 'New Targets and Approaches to the Treatment of Epilepsy'.

KW - animals

KW - anticonvulsants

KW - arachidonic acids

KW - calcium channel blockers

KW - cannabinoid receptor antagonists

KW - dose-response relationship, drug

KW - electroencephalography

KW - endocannabinoids

KW - epilepsy, absence

KW - ethanolamines

KW - glycerides

KW - injections, intraventricular

KW - lipid metabolism

KW - male

KW - oxazoles

KW - PPAR alpha

KW - palmitic acids

KW - piperidines

KW - polyunsaturated alkamides

KW - pyrazoles

KW - rats

KW - rats, wistar

KW - receptor, cannabinoid, CB1

KW - tyrosine

U2 - 10.1016/j.neuropharm.2012.11.017

DO - 10.1016/j.neuropharm.2012.11.017

M3 - Article

VL - 69

SP - 115

EP - 126

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

ER -